Open in interactive viewer → charts, metric popovers & call review

IL MAKIAGE Still Won't Load — So ODDITY Is Buying a Peptide Future

A Q3 beat built on repeat orders and cost discipline, while the real story is METHODIQ's leap into HHS-blessed peptides, longevity and metabolic health
ODD · Earnings Call · 2026-11-11

The Beat Nobody Was Watching For

ODDITY Tech came into 2026 with a hole in its growth engine and spent three quarters explaining it. On 2026-11-11 the company put up net revenue of $145 million, down 2% year over year — a dramatic improvement from the 25% decline reported in Q2 — and adjusted EBITDA of $22 million against a guidance range of $18–20 million. Management raised full-year revenue guidance to a decline of roughly 18.5% and lifted adjusted EBITDA to $32–34 million. The numbers are the least interesting thing on this call. The most interesting thing is that a company whose entire identity has been "we are a marketing machine with 70 million users" just made its boldest non-marketing bet yet: new categories in longevity and metabolic health, including prescription peptides, unlocked by a government policy shift.

The Algorithm That Won't Heal

The ad account problem — a stubborn dislocation with IL MAKIAGE's largest advertising partner — is now a four-quarter saga, and the language has subtly hardened. In February, Oran Holtzman was adamant the problem was mechanical: “we know that the current numbers that we see in user acquisition are completely off market, and we know it's — and therefore, we believe it's something technical” — Oran Holtzman, Co-Founder and CEO · 2026-02-25. By June, CFO Lindsay Drucker Mann was quantifying the prize: “they estimate that we can recover 40% to 60% of CPA” — Lindsay Mann · 2026-06-02. By September the recovery had slipped to hope: “We are not there yet. We did not solve it yet. But we believe that we are closer than before” — Oran Holtzman, Co-founder and CEO · 2026-09-09. This quarter the honesty got sharper, and that is the tell. Holtzman no longer offers a trajectory — he offers volatility: “September was the best CPA that we had since earlier this year, but it's very volatile. So October wasn't that good, but we are here to fix the problem and not just to improve it slightly” — Oran Holtzman, Co-founder and CEO · 2026-11-11. The company asks to be judged on a repair it cannot yet demonstrate, and the algorithm dislocation remains the single largest swing factor in the business. The offset is that the rest of the machine held. More than 80% of revenue came from repeat orders, which stabilized versus last year, and first-order revenue (down high teens) no longer dragged the whole company under. SpoiledChild is on track to grow at least 35% to roughly $350 million, and the company continues to shrink its share count aggressively — 11.7 million shares repurchased for $163 million in the first nine months, about a 20% reduction year to date, with $86 million left on the authorization and $561 million of cash and investments plus $350 million of undrawn facilities. This is a company using its balance sheet to buy time while it fixes a problem it insists is fixable.

The Pivot: From Lipstick to Longevity

Here is where the call genuinely changed. ODDITY has spent years describing itself as a platform that identifies user base demand and scales into it. This quarter it applied that ODDITY platform logic to something far outside beauty: prescription injectables. Holtzman laid out the sequence plainly — NAD+, Sermorelin and others prescribed through licensed providers and filled by U.S. licensed pharmacy partners, followed by six additional peptide therapies covered by the enforcement discretion policy published by HHS last month. “we launched METHODIQ with 30 products, and now we have very promising rollout for 2027 for METHODIQ, including peptides for the first time” — Oran Holtzman, Co-founder and CEO · 2026-11-11. This is a company-unique signal, not sector boilerplate. The word peptide is the single biggest gainer in ODDITY's own keyword history this quarter, and metabolic health surfaced as a top-tier theme for the first time. It also plugs into a genuine market wave: across the global tape, GLP 1 growth and weight-health language are showing up in advancers and in other recent reporters' calls, so ODDITY is riding a real secular current rather than inventing one. The strategic logic is that METHODIQ already built the hard infrastructure — clinical intake, provider networks, national pharmacy fulfillment — for dermatology prescriptions, and extending it to peptides is incremental rather than greenfield. Holtzman's framing of why a crowded market is actually a help is worth noting: “I think that the fact that it's new, it's easier for us to compete. Yes, the market is being opened now, but the fact that we are already ready to go” — Oran Holtzman, Co-founder and CEO · 2026-11-11. The company also insists this is not a land grab dressed as strategy.

we're not spending any dollar against any product or any category that is not highly profitable on a 12-month basis. So even if the investment is higher, for example, for peptides in the beginning, if the payback will not be materially better than other categories, we will not spend money against it.

Oran Holtzman, Co-founder and CEO · 2026-11-11
That discipline claim will be the thing to test in 2027, because acquiring peptide customers is expected to cost more upfront than the mature base business.

What Management Stopped Emphasizing

The subtler signal is in what faded. For several quarters the call rang with dermatology, hyperpigmentation, eczema and the vision-technology pitch behind METHODIQ's medical-grade offering. This quarter those themes thinned out, and even the word "prescription" — the backbone of METHODIQ's original pitch — fell sharply in ODDITY's keyword trajectory as the narrative shifted toward injectables and peptides. That is not abandonment, but it is a reprioritization: the story is moving from skin conditions toward a broader wellness-and-longevity menu, which is a bigger prize and a bigger execution risk in one move. The financial reality underneath is less glamorous. Gross margin compressed to 67.4% from 71.6%, and “AOV was down around mid-single digits and the AOV decline is driven in part by the fact that we've got a big reduction in our first orders and first-order AOVs are higher than repeat-order AOV” — Lindsay Mann, Global CFO · 2026-11-11. Inventory sits at $158 million, heavy at IL MAKIAGE, though management notes low obsolescence and expects to be back in balance in 2027. Notably, Holtzman would not entertain a distribution pivot to Amazon even as an analyst pushed: “IL MAKIAGE needs to go back to growth, and that's what I do day and night” — Oran Holtzman, Co-founder and CEO · 2026-11-11. The company is doubling down on D2C at exactly the moment its largest D2C channel is broken. That is the tension of this report. A $1.1 billion-market-cap company is asking investors to believe two things at once: that a technical advertising problem will be solved, and that the next decade of growth lives in peptides rather than powder. The Q3 beat buys credibility for the first. The peptide pivot is a bet that the second matters more. For a stock that once jumped 26.5% on a report showing sales down 25%, the bar for surprise is low — which is precisely why a genuine new growth engine is the more meaningful disclosure.